Ignite Creation Date:
2024-05-06 @ 5:47 PM
Last Modification Date:
2024-10-26 @ 2:35 PM
Study NCT ID:
NCT05431504
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-06-24
First Post:
2022-06-19
Brief Title:
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization Data
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Class:
OTHER
Study ID:
MA-BC-II-033
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Jiangsu HengRui Medicine Co Ltd | INDUSTRY |